Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Stavitskaya (Novosibirsk, Russian Federation), S. Smerdin (Moscow, Russian Federation), D. Kudlay (Moscow, Russian Federation), N. Doktorova (Moscow, Russian Federation), O. Tlif (Moscow, Russian Federation), T. Petrenko (Novosibirsk, Russian Federation), T. Kolpakova (Novosibirsk, Russian Federation). Multivariate analysis of the effectiveness of bedaquiline-containing chemotherapy regimens in previously treated XDR TB patients. 1597

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Use of shortened chemotherapy regimens in treatment of adolescents with MDR/XDR TB Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47:1758-1766 Year: 2016 Safety and efficacy of supervised chemotherapy in Indian patients having multi-drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012